8-K: CytoSorbents Faces Nasdaq Listing Scrutiny

CytoSorbents Corporation received a notice from Nasdaq indicating non-compliance with minimum market value requirements, with 180 days to regain compliance.

Summary

• CytoSorbents Corporation received a written notice from Nasdaq on June 29, 2026, stating it is not in compliance with Nasdaq Listing Rule 5550(b)(2).
• The company's Market Value of Listed Securities (MVLS) fell below the required $35 million for continued listing on the Nasdaq Capital Market.
• Nasdaq has granted the company 180 calendar days, until December 28, 2026 (the Compliance Date), to regain compliance.
• To comply, the company's common stock market value must meet or exceed $35 million for at least 10 consecutive business days within the grace period.
• The company is exploring actions to regain compliance, including monitoring its market value and potentially increasing stockholders' equity to at least $2.5 million.
• Failure to regain compliance by the deadline could result in delisting, though an appeal process is available.
• There is no assurance the company will successfully maintain its Nasdaq listing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the immediate threat of delisting from Nasdaq, despite the grace period provided.

Positives

• The company has been granted a 180-day grace period to regain compliance with Nasdaq's listing standards.
• The notice does not immediately result in the delisting of the company's common stock.
• The company is actively evaluating potential actions to regain compliance.

Negatives

• The company is not in compliance with Nasdaq Listing Rule 5550(b)(2) due to its Market Value of Listed Securities being below the $35 million minimum.
• There is a risk of delisting from the Nasdaq Capital Market if compliance is not achieved by December 28, 2026.
• There is no guarantee that the company will be successful in maintaining its listing.

Risks

• Failure to meet the minimum Market Value of Listed Securities requirement of $35 million for 10 consecutive business days by December 28, 2026.
• Potential delisting from the Nasdaq Capital Market if compliance is not achieved.
• The company may not be successful in implementing actions to increase its market value or stockholders' equity.
• The possibility of an appeal of a delisting determination if compliance is not met.

Future Outlook

The company is actively evaluating potential actions to regain compliance with Nasdaq's listing standards, including monitoring its market value and potentially increasing stockholders' equity. There is no assurance of success in maintaining its listing.

Management Comments

• The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its listed securities.
• The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standard such as by increasing its stockholders equity to at least $2.5 million.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is crucial for investor confidence and liquidity. Companies facing MVLS deficiencies often explore strategies such as reverse stock splits, asset sales, or capital raises to meet requirements, though success is not guaranteed.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to the risk of delisting, which could reduce liquidity and investor interest.
• Creditors: May face increased risk if delisting leads to financial instability.
• Employees: Uncertainty regarding company stability and future prospects.

Next Steps

• Regain compliance with the Market Value of Listed Securities requirement by ensuring the market value meets or exceeds $35 million for at least 10 consecutive business days by December 28, 2026.
• Alternatively, increase stockholders' equity to at least $2.5 million.
• Actively monitor the market value of listed securities.
• Consider other options to regain compliance if necessary.
• If compliance is not achieved, prepare for potential delisting and consider an appeal.

Key Dates

Recommendation

The filing indicates a significant risk of delisting, which is a negative development. However, the company has a 180-day grace period and is exploring options to regain compliance. A 'hold' recommendation is appropriate given the uncertainty; investors should monitor the company's progress towards meeting Nasdaq's requirements before making further decisions.

Keywords

CytoSorbents, Nasdaq, Listing Rule, Market Value, Delisting, Compliance, Form 8-K, Securities, Stockholders Equity